Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

NCT02945319 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT02945319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02945319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Observational
Overall status
Completed
Start date
January 31, 2017
Completion date
December 31, 2020
Enrollment
373 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

splenic marginal zone lymphoma